Atossa Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $24.5M
- Price
- $2.46
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.41%
- Volume
- 19.1K
About
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
Quick stats
Shares outstanding10.0M
Computed float10.0M
Float / shares100.0%
Cash runway (months)4.8
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001488039
AI Summary
AI-generated1/22
minorbullishother
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
Atossa Therapeutics' Board approved a plan to issue one contingent value right per ATOS share, tied to monetization of the company's first qualifying rare pediatric disease priority review voucher.
CVR holders would receive 25% of net proceeds from a qualifying voucher monetization, capped at $50 million in aggregate; CVRs would trade stapled to ATOS shares with no separate registration or CUSIP.
No voucher has been awarded to date and (Z)-endoxifen is not approved, so no CVR payment is assured; CVRs would expire if no qualifying voucher is awarded by December 31, 2036. Past voucher sales have ranged from $100 million to $220 million.
Red flags
- No Atossa product candidate is approved and no voucher has been awarded — CVR payments are entirely contingent
- CVR capped at $50 million aggregate and subject to 'legally permitted distributions and solvency' provisions
- Voucher value is variable; past sales of $100M-$220M are not indicative of future value